A study on changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma.
The authors conducted an investigation focusing mainly on the activities of the inhibitory factors of the coagulation and fibrinolysis processes in 35 normal adults and 72 liver cirrhosis and/or hepatoma patients. The activities of antithrombin III, protein C, and alpha 2-plasmin inhibitor were reduced to less than 50% in patients with decreased hepatic synthetic function while lupus anticoagulant was detected in more than 50% of patients with decreased hepatic synthetic function. Hemostatic abnormalities in advanced lived diseases may be caused partly by a decrease of coagulation and fibrinolysis inhibitors and the presence of lupus anticoagulant.
Park
C J
CJ
Department of Clinical Pathology, College of Medicine, Hallym University, Seoul, Korea.
Cho
H I
HI
Kim
S I
SI
D000328:Adult; D000933:Antifibrinolytic Agents / Q000097:blood; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000097:blood*; D006487:Hemostasis; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood*; D008113:Liver Neoplasms / Q000097:blood*; D016682:Lupus Coagulation Inhibitor
D000933:Antifibrinolytic Agents; D001779:Blood Coagulation Factors; D016682:Lupus Coagulation Inhibitor